AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict the shape of not only proteins but also DNA, RNA and other biological building blocks. Moreover, the algorithm does so more reliably than earlier models.

Alphabet created Isomorphic Labs in 2021, spinning it out from DeepMind, the AI startup it acquired in 2014. DeepMind’s leader, Demis Hassabis, who runs Google’s AI efforts, is also the chief executive officer of Isomorphic Labs. Last year, the company announced partnerships with Novartis AG and Eli Lilly & Co.

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding within Google parent company Alphabet,